(Q69832370)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

title

Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

author name string

J L Jurlina

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

A R Varcoe

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

publication date

1 January 1985

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

6 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

page(s)

21-25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3855288%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00552719

6 October 2019

exact match

0 references

cites work

The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series

1 reference

12 December 2020

Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule

1 reference

12 December 2020

Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule

1 reference

12 December 2020

The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer

1 reference

12 December 2020

Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group

1 reference

12 December 2020

Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults

1 reference

12 December 2020

Phase I-II study of m-AMSA administered as a continuous infusion

1 reference

12 December 2020

Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics

1 reference

12 December 2020

Phase I and II study of AMSA in childhood tumours

1 reference

12 December 2020

4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia

1 reference

12 December 2020

Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine

1 reference

12 December 2020

Potential antitumor agents. 14. Acridylmethanesulfonanilides.

1 reference

12 December 2020

Potential antitumor agents. 12. 9-Anilinoacridines

1 reference

12 December 2020

High-performance liquid-chromatographic method for the determination of 4'-(9-acridinylamino)methanesulfon-m-anisidide in plasma

1 reference

12 December 2020

Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study

1 reference

12 December 2020

Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992)

1 reference

12 December 2020

Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.

1 reference

12 December 2020